COMMUNIQUÉS West-GlobeNewswire
-
The American Health Council Physician Board Appoints Laura Rainer, MD
24/11/2017 - 14:00 -
Galapagos increases share capital through warrant exercises
23/11/2017 - 22:02 -
Canada House’s Knalysis Technologies’ Self-Registration Drives Efficiency for US Customers
23/11/2017 - 16:43 -
Crown Bioscience and Data Sciences International (DSI) Partner to Advance Metabolic Disease Research Using an Implanted Telemetry Device for Long-Term Blood Glucose Monitoring
23/11/2017 - 14:00 -
Guerbet reinforces its expertise with the launch of Contrast&Care®, a contrast media injection management solution for radiology centers
23/11/2017 - 08:02 -
Guerbet renforce son expertise avec le lancement de Contrast&Care®, une solution de gestion de l'injection des produits de contraste pour les centres d'imagerie médicale
23/11/2017 - 08:02 -
Saniona AB: Saniona AB's Nomination Committee for the 2018 Annual General Meeting
23/11/2017 - 08:01 -
THIRD GLOBAL IRON DEFICIENCY DAY TO RAISE AWARENESS OF THE SYMPTOMS OF IRON DEFICIENCY
23/11/2017 - 07:01 -
Probiodrug : Probiodrug AG to Publish its Third Quarter 2017 Business Update on 30 November 2017
23/11/2017 - 07:00 -
IGC Announces Adjournment of Annual Meeting Voting for Proposals Three and Four to Dec 15, 2017
22/11/2017 - 23:00 -
Forward Pharma Announces Completion of Corporate Restructuring Plan
22/11/2017 - 22:30 -
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
22/11/2017 - 22:30 -
RedHawk Announces First Quarter Results
22/11/2017 - 22:30 -
Cannevert Scientists to Present Their First Peer-Reviewed Research at December’s Prestigious British Pharmacological Society Meeting in London, UK
22/11/2017 - 22:15 -
TESARO Announces Participation in Two Investor Conferences
22/11/2017 - 22:05 -
Prothena to Participate in the Evercore ISI Biopharma Catalyst/Deep Dive Conference
22/11/2017 - 22:05 -
Adamas to Present at Two Upcoming Investor Conferences
22/11/2017 - 18:42 -
GENFIT: Positive Outcome from the 18-month Pre-Planned Safety Review by the DSMB, in RESOLVE-IT Phase 3 Clinical Trial with elafibranor
22/11/2017 - 18:19 -
GENFIT : issue positive du DSMB suite à la revue planifiée à 18 mois des données de tolérance et de sécurité d'emploi d'elafibranor, dans l'étude clinique de Phase 3 RESOLVE-IT
22/11/2017 - 18:19
Pages